Aspire Biopharma's Subsidiary, Buzz Bomb Caffeine Company, Appoints John Choe as Western Sales Director

Rhea-AI Summary

Aspire Biopharma (Nasdaq:ASBP) announced on March 17, 2026 that subsidiary Buzz Bomb Caffeine Company appointed John Choe as Western Sales Director. Choe is described as a 25-year industry veteran with prior roles at Yerbaé (2016–2025) and a reported 70% sales increase.

The announcement highlights Choe's experience in retail and beverage distribution, DSD and wholesale relationships, multilingual skills, and his MBA and BS degrees as assets to scale Buzz Bomb's western U.S. sales efforts.

Key Figures

Sales increase: 70% increase in overall sales Caffeine dose: 50mg per stick Alprazolam prescriptions: Over 15.8 million prescriptions +5 more

8 metrics

Sales increase 70% increase in overall sales Yerbaé tenure in natural energy drink category (2016-2025)

Caffeine dose 50mg per stick BUZZ BOMB single-serving dry powder caffeine product

Alprazolam prescriptions Over 15.8 million prescriptions U.S. alprazolam prescriptions in 2023 cited for market size

Alprazolam market size $55.84 billion Projected global alprazolam powder market by 2032

Social media reach 400,000 views in 48 hours Buzz Bomb content following 2026 Jackpot Ultra Running Festival sponsorship

Equity requirement $2.5 million stockholders’ equity Nasdaq Listing Rule 5550(b)(1) compliance achieved by 2026-02-20

Initial Trust Account Approximately $294.7 million Initial Trust Account funding described in S-1 IPO registration

Trust balance $6.67 million Trust Account balance at December 31, 2024 after redemptions

Market Reality Check

Price: $0.0209 Vol: Volume 600 vs 20-day aver...

low vol

$0.0209 Last Close

Volume Volume 600 vs 20-day average 11,382 (relative volume 0.05) shows limited trading interest into this leadership announcement. low

Technical Shares trade below the 200-day MA, with price at 0.01771 versus MA 0.04, indicating a weak longer-term setup pre-news.

Peers on Argus

ASBPW fell 5.85% while sector warrants showed mixed moves: some peers like LEXXW...

ASBPW fell 5.85% while sector warrants showed mixed moves: some peers like LEXXW and CINGW rose sharply, others like LIXTW and BCTXW declined. This mix, plus no peers in the momentum scanner, points to a stock-specific reaction rather than a coordinated sector move.

Historical Context

5 past events · Latest: Mar 12 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 12	Trade show marketing	Positive	-7.5%	Buzz Bomb featured at The Health & Fitness Show to promote flagship product.
Mar 10	Product launch	Positive	-5.7%	Launch of BUZZ BOMB Convenience Store Pack targeting convenience retail channel.
Mar 03	Strategic partnership	Positive	-17.4%	Partnership with Microsize to develop rapid-delivery sublingual alprazolam powder.
Feb 25	Marketing & branding	Positive	+18.1%	World-record marathon sponsorship drove social media growth and sales gains.
Feb 20	Listing compliance	Positive	+3.9%	Regained full compliance with Nasdaq equity and minimum bid requirements.

Pattern Detected

Recent history shows frequent negative reactions to broadly positive news, with 3 of the last 5 announcements followed by declines.

Recent Company History

Over the past month, Aspire Biopharma has focused on building both its Buzz Bomb consumer brand and its pharmaceutical pipeline. Commercially, it launched a convenience store pack and promoted BUZZ BOMB™ at The Health & Fitness Show, yet shares fell after the 2026-03-10 and 2026-03-12 releases. A strategic alprazolam partnership on 2026-03-03 also saw a -17.36% move. In contrast, a world-record marathon sponsorship and Nasdaq compliance news on 2026-02-25 and 2026-02-20 drew positive price reactions, highlighting inconsistent follow-through on good news.

Market Pulse Summary

This announcement adds a seasoned sales leader with a track record of driving a 70% sales increase i...

Analysis

This announcement adds a seasoned sales leader with a track record of driving a 70% sales increase in the energy drink space to Aspire Biopharma’s Buzz Bomb subsidiary. It follows recent BUZZ BOMB™ product launches, trade show exposure, and a separate alprazolam development partnership. Investors may watch for concrete metrics such as distribution gains, repeat orders, and revenue trends, alongside continued compliance with listing standards and funding progress, to assess the impact of these strategic moves.

Key Terms

s.w.o.t. analysis, direct store delivery, definitive proxy statement, ipo, +2 more

6 terms

s.w.o.t. analysis technical

"His strategic use of S.W.O.T. analysis and his ability to navigate complex DSD..."

A s.w.o.t. analysis is a straightforward checklist that catalogs an organization’s internal Strengths and Weaknesses alongside external Opportunities and Threats. For investors it’s like a quick health and neighborhood check: it highlights where a business has advantages or vulnerabilities and where market conditions could help or hurt future performance, helping assess risk, growth potential, and strategic fit in a portfolio.

direct store delivery technical

"navigate complex DSD (Direct Store Delivery) and wholesale relationships..."

Direct store delivery is a distribution method where a supplier or manufacturer ships products straight to individual retail stores instead of sending them through the retailer’s central warehouse. For investors, it matters because it affects a company’s sales speed, inventory costs, product freshness and retailer relationships — similar to a bakery bringing fresh bread directly to cafes instead of routing it through a middle warehouse, which can boost turnover but raise delivery costs and operational complexity.

definitive proxy statement regulatory

"The filing is a Definitive Proxy Statement for Aspire Biopharma Holdings, Inc...."

A Definitive Proxy Statement is a detailed document that a company sends to its shareholders before a big meeting, like voting on important decisions. It explains what's being voted on and gives important information so shareholders can make informed choices. It matters because it helps shareholders understand and participate in key company decisions.

ipo financial

"Aspire Biopharma Holdings, Inc. (ASBPW) S-1 describes the company’s IPO-related capital structure..."

An initial public offering (IPO) is the process by which a private company sells its shares to the public for the first time, making its ownership available on the stock market. This allows the company to raise money from a wide range of investors to fund growth or other goals. For investors, an IPO offers a chance to buy into a company early in its public journey, potentially benefiting if the company grows in value.

trust account financial

"Unit offering that funded a Trust Account (approximately $294.7 million initially)..."

A trust account is a special bank or brokerage account where assets are held and managed by a designated person or firm (the trustee) for the benefit of another person or group (the beneficiary). It matters to investors because it separates assets from personal or corporate funds, can protect assets, control how and when money is used, and may affect tax or legal rights—think of it as a locked drawer opened only under agreed rules.

original-issue-discount financial

"multiple original-issue-discount (OID) notes to related parties, and convertible/debt instruments..."

A debt security sold for less than its face value, so the buyer pays below the amount the issuer will repay at maturity; for example, buying a $100 bond for $90. That difference is the original-issue discount and acts like extra interest income for the investor, boosting the effective yield beyond the stated coupon. Investors care because OID changes expected return, cash-flow timing and tax treatment — similar to getting a built-in discount that increases your profit when the loan is repaid.

AI-generated analysis. Not financial advice.

ESTERO, FL / ACCESS Newswire / March 17, 2026 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire"), wholly owned subsidiary, Buzz Bomb Caffeine Company, has appointed 25-year industry veteran John Choe as Western Sales Director. Choe joins the leadership team with a distinguished career of scaling consumer brands and leading high-performance teams across the retail and beverage sectors.

Choe joins Buzz Bomb following a successful tenure as District Manager at Yerbaé (2016-2025), where he specialized in the natural energy drink category, achieving a 70% increase in overall sales within a highly competitive market. He accomplished this by spearheading the development of brand ambassador programs and innovative marketing tools tailored to both identified and untapped consumer segments. His strategic use of S.W.O.T. analysis and his ability to navigate complex DSD (Direct Store Delivery) and wholesale relationships with partners like WinCo, KeHE, and Kroger was instrumental to his success.

"John's deep expertise in the beverage and retail sectors, combined with a visionary approach to market analysis and consumer engagement, makes him an ideal leader to spearhead our sales strategy in the western United States," stated Kraig Higginson, Interim CEO of Aspire Biopharma. "The ability to build productive relationships and a creative approach to reaching both identified and untapped consumer segments will be instrumental as the brand continues to scale."

Choe's extensive background includes pivotal roles at global brands such as:

Nike (1999-2005): Managed major accounts like Nordstrom and specialized in futures ordering across Northern and Southern California.

Mars Candy (2005-2009): Led sales and merchandising efforts for massive retail outlets including Walmart, Target, and Safeway.

Bosch (2009-2012): Spearheaded training and product education for retail giants Home Depot, Lowe's, and Ace Hardware.

With 11 years of dedicated supervisory experience, Choe is a specialist in hiring, mentoring, and coaching direct reports to peak performance. His leadership style emphasizes compliance, accountability, and the development of talent. Furthermore, his fluency in Korean, Chinese, and Japanese provides a unique edge in engaging with diverse markets.

"I am thrilled to join BUZZ BOMB^™ at such a pivotal moment in its growth trajectory," said John Choe. "The energy category is evolving quickly, and I look forward to leveraging my experience in retail partnerships to expand our footprint and bring Buzz Bomb's innovative products to a wider audience."

John Choe holds a Master of Business Administration from the University of Phoenix and a Bachelor of Science in Business Management from the University of Utah.

BUZZ BOMB^™ Caffeine Products

To learn more about BUZZ BOMB^™, or purchase product online, please visit https://buzzbombcaffeine.com or follows us on social media here:

Facebook

Instagram

TikTok

About Aspire Biopharma Holdings, Inc.

Aspire Biopharma delivers supplements to the body rapidly and precisely.

For more information, please visit www.aspirebiolabs.com

Aspire Biopharma Holdings, Inc.

Contact

PCG Advisory
Kevin McGrath
+1-646-418-7002
kevin@pcgadvisory.com

Safe Harbor Statement

This press release contains "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, which are intended to be covered by the "safe harbor" provisions created by those laws. Aspire's forward-looking statements include, but are not limited to, statements regarding our or our management team's expectations, hopes, beliefs, intentions or strategies regarding our future operations. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words "anticipate," "believe," "contemplate," "continue," "estimate," "expect," "intends," "may," "might," "plan," "possible," "potential," "predict," "project," "should," "will," "would," and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements represent our views as of the date of this press release and involve a number of judgments, risks and uncertainties. We anticipate that subsequent events and developments will cause our views to change. We undertake no obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date. As a result of a number of known and unknown risks and uncertainties, our actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ in our drug or supplement offerings include general market conditions, whether clinical trials demonstrate the efficacy and safety of our drug candidates to the satisfaction of regulatory authorities, or do not otherwise produce positive results which may cause us to incur additional costs or experience delays in completing, or ultimately be unable to complete the development and commercialization of our drug candidates; the clinical results for our drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; our ability to achieve commercial success for our drug or supplement candidates, if approved; our limited operating history and our ability to obtain additional funding for operations and to complete the development and commercialization of our product candidates, and other risks and uncertainties set forth in "Risk Factors" in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q. In addition, statements that "we believe" and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this press release, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and you are cautioned not to rely unduly upon these statements. All information in this press release is as of the date of this press release. The information contained in any website referenced herein is not, and shall not be deemed to be, part of or incorporated into this press release.

SOURCE: Aspire Biopharma Holdings, Inc.

View the original press release on ACCESS Newswire

FAQ

Who is John Choe and what role did Aspire Biopharma (ASBP) name him to on March 17, 2026?

John Choe was named Western Sales Director for Buzz Bomb, a subsidiary of Aspire Biopharma. According to the company, he is a 25-year industry veteran with prior roles at Yerbaé and major retail account experience.

What experience did John Choe bring to Buzz Bomb as reported by Aspire Biopharma (ASBP)?

Choe brings extensive retail and beverage sales experience, including DSD and wholesale channel management. According to the company, his background includes roles at Yerbaé, Nike, Mars Candy, and Bosch.

What specific achievement from John Choe's tenure at Yerbaé did Aspire Biopharma (ASBP) highlight?

Aspire highlighted a reported 70% increase in overall sales during Choe's Yerbaé tenure. According to the company, he achieved this through brand ambassador programs and targeted marketing tactics.

How will John Choe's appointment affect Buzz Bomb's sales strategy in the western U.S. according to Aspire Biopharma (ASBP)?

The appointment is intended to strengthen Buzz Bomb's western U.S. sales execution and retail partnerships. According to the company, Choe's skills in building relationships and channel navigation will support expansion efforts.

What qualifications and languages does John Choe have as noted by Aspire Biopharma (ASBP)?

Choe holds an MBA and a BS in Business Management and speaks Korean, Chinese, and Japanese. According to the company, these qualifications support engagement with diverse markets and talent development.